Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Guvenc, Deborah Keefe, Kai Grosch, Michele L Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Dei Adomakoh

Blood (2023) 142 (Supplement 1): 272.

https://doi.org/10.1182/blood-2023-185429

Published: 2023

Journal Articles

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Blood (2023) 142 (Supplement 1): 271.

https://doi.org/10.1182/blood-2023-187033

Published: 2023

Journal Articles

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

Matthew M. Heeney, Miguel R. Abboud, Jessie Githanga, Baba P. D. Inusa, Julie Kanter, Alan D. Michelson, Videlis Nduba, Victor Musiime, Mohini Apte, Adlette Inati, Amar M. Taksande, Marielle Andersson, Magnus Åstrand, Noha Maklad, Mohammad Niazi, Anders Himmelmann, Anders R. Berggren

Blood (2022) 140 (13): 1470–1481.

https://doi.org/10.1182/blood.2021014095

Published: 2022

Includes: Supplemental data

Journal Articles

Experiences of Sickle Cell Disease (SCD) Reported By Healthcare Professionals (HCPs) across Different Regions: International Sickle Cell World Assessment Survey (SWAY)

Blood (2021) 138 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2021-145409

Published: 2021

Journal Articles

Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-137103

Published: 2020

Journal Articles

An Age Analysis of the International Sickle Cell World Assessment Survey (SWAY), Focusing on Symptoms, Treatment Goals and the Impact of SCD on Patients' Daily Lives

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-136073

Published: 2020

Journal Articles

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Wally R Smith, MD, Jane S. Hankins, MD MS, Miguel R Abboud, MD, Ze Cong, PhD, Jonathan Sorof, MD, Sarah Gray, PhD, Carolyn Hoppe, MD, Paul Telfer, DM, FRCP

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137121

Published: 2020

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)

John James, MSc, Biree Andemariam, MD, Baba PD Inusa, MD, Fuad El-Rassi, Beverly Francis-Gibson, Alecia C. Nero, MD, Caterina P. Minniti, MD, Cassandra Trimnell, BA, Miguel R. Abboud, MD, Jean-Benoît Arlet, Raffaella Colombatti, Mariane de Montalembert, MD PhD, Suman Jain, Wasil Jastaniah, Erfan Nur, MD PhD, Laurie DeBonnett, MD, Ifeyinwa (ify) Osunkwo, MD MPH

Blood (2019) 134 (Supplement_1): 1017.

https://doi.org/10.1182/blood-2019-123643

Published: 2019

Journal Articles

Impact of Sickle Cell Disease Symptoms on Patients' Daily Lives: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)

Ifeyinwa (ify) Osunkwo, MD MPH, Biree Andemariam, MD, Baba PD Inusa, MD, Fuad El-Rassi, Beverly Francis-Gibson, Alecia C. Nero, MD, Caterina P. Minniti, MD, Cassandra Trimnell, BA, Miguel R. Abboud, MD, Jean-Benoît Arlet, Raffaella Colombatti, Mariane de Montalembert, MD PhD, Suman Jain, Wasil Jastaniah, MBBS, FRCPC, Erfan Nur, MD PhD, Laurie DeBonnett, MD, John James, MSc

Blood (2019) 134 (Supplement_1): 2297.

https://doi.org/10.1182/blood-2019-124762

Published: 2019

Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD

Blood (2019) 134 (Supplement_1): 1003.

https://doi.org/10.1182/blood-2019-130767

Published: 2019

Journal Articles

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Baba PD Inusa, MD, Adlette Inati, MD, Philip Maes, MD, Jessie Githanga, MBChB, MMed, Miguel R. Abboud, MD, Maurizio Miano, Elena Cela, Videlis Nduba, Mohammad Niazi, Magnus Åstrand, Kevin Persson, Anders Rikard Berggren, MD PhD, Glenn Carlson, MD

Blood (2019) 134 (Supplement_1): 1005.

https://doi.org/10.1182/blood-2019-129855

Published: 2019

Journal Articles

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Miguel R. Abboud, MD, Jo Howard, MB, BChir, Rodolfo Cançado, Wally R Smith, MD, Birol Güvenç, MD, Noemi Espurz, Marine Weill, Mariane de Montalembert, MD PhD

Blood (2019) 134 (Supplement_1): 998.

https://doi.org/10.1182/blood-2019-125775

Published: 2019

Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer

Blood (2018) 132 (Supplement 1): 509.

https://doi.org/10.1182/blood-2018-99-117510

Published: 2018

Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Blood (2018) 132 (Supplement 1): 505.

https://doi.org/10.1182/blood-2018-99-118508

Published: 2018

Journal Articles

Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon

Habib El-Khoury, B.Sc., MD Candidate, Khaled M Ghanem, MD, Yaacoub Mubarak, Nidale Tarek, MD, Hassan El Solh, Anthony K.C. Chan, MBBS, Carole Aridi, Miguel R. Abboud, Raya Saab, MD, Samar A. Muwakkit, MD

Blood (2018) 132 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2018-99-119638

Published: 2018

Journal Articles

Narrowing the Gap for Hematopoietic Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends. A Report on Behalf of the East Mediterranean (EMBMT), African Blood and Marrow Transplantation Group (AFBMT) and Worldwide Network for Blood and Marrow Transplantation (WBMT)

Blood (2017) 130 (Supplement 1): 3389.

https://doi.org/10.1182/blood.V130.Suppl_1.3389.3389

Published: 2017

Journal Articles

Decreasing Dose and Duration of Dexamethasone Therapy for Low-Risk Childhood Acute Lymphoblastic Leukemia Aiming to Avoid Serious Viral Infections Results in Significant Increase in Isolated CNS Relapse: A Prospective Study

Khaled M Ghanem, MD, Miguel R Abboud, MD, Nidale Tarek, MD, Raya Saab, MD, Hani Tamim, PhD, Hassan El-Solh, MD, Samar A. Muwakkit, MD

Blood (2017) 130 (Supplement 1): 1284.

https://doi.org/10.1182/blood.V130.Suppl_1.1284.1284

Published: 2017

Journal Articles

Fludarabine-Based Reduced Intensity Regimen for Matched Related Donor Stem Cell Transplantation in Acquired Severe Aplastic Anemia

Khaled M Ghanem, MD, Mohamed A. Kharfan-Dabaja, MD, Hassan El-Solh, MD, Nariman Harris, Nabila Kreidieh, Rita Nehme, Samar A. Muwakkit, MD, Raya Saab, MD, Ali Bazarbachi, MD PhD, Miguel R Abboud, MD

Blood (2016) 128 (22): 5753.

https://doi.org/10.1182/blood.V128.22.5753.5753

Published: 2016

Journal Articles

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study

Baba Inusa, Raffaella Colombatti, MD PhD, David C Rees, MA, FRCP, Matthew M Heeney, MD, Carolyn C Hoppe, MD, Bernhards Ogutu, MD PhD, Hoda M Hassab, MD, Chunmei Zhou, MS, Suqin Yao, PhD, Patricia B Brown, BSN, RN, Lori E Heath, MS, Joseph A. Jakubowski, PhD, Miguel R Abboud, MD

Blood (2016) 128 (22): 3653.

https://doi.org/10.1182/blood.V128.22.3653.3653

Published: 2016

NARROW

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

Experiences of Sickle Cell Disease (SCD) Reported By Healthcare Professionals (HCPs) across Different Regions: International Sickle Cell World Assessment Survey (SWAY)

Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU

An Age Analysis of the International Sickle Cell World Assessment Survey (SWAY), Focusing on Symptoms, Treatment Goals and the Impact of SCD on Patients' Daily Lives

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)

Impact of Sickle Cell Disease Symptoms on Patients' Daily Lives: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon

Decreasing Dose and Duration of Dexamethasone Therapy for Low-Risk Childhood Acute Lymphoblastic Leukemia Aiming to Avoid Serious Viral Infections Results in Significant Increase in Isolated CNS Relapse: A Prospective Study

Fludarabine-Based Reduced Intensity Regimen for Matched Related Donor Stem Cell Transplantation in Acquired Severe Aplastic Anemia

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only